CCIT-DK: National Center for Cancer Immune Therapy
@CCITdk
Followers
454
Following
497
Media
72
Statuses
244
Bridging the gap between discovery and clinical implementation in #cancer #immunotherapy #immunooncology at @HerlevGentofte Copenhagen. SoMe manager @doniamarco
Capital Region, Denmark
Joined April 2018
🆕 Nationwide real-world (DAMMED 🇩🇰) study comparing Dab/Tram vs Enco/Bini in 751 pts with BRAFm metastatic melanoma. ⚖️ No differences in efficacy 🧩 Consistent across subgroups (incl. 🧠 mets) 📄 https://t.co/ENrLzdQ0Yq In @JNCI_Now
@CCITdk @DoniaMarco #Melanoma #Oncology
3
2
7
@CCITdk is happy to support the candidacy of Professor @ulassen to this important post at ESMO @myESMO
I am pleased and proud to be a candidate running in the election for the position of Nomination Committee Member for ESMO ESMO - @myESMO @Rigshospitalet @OECI_EEIG @ASCO
https://t.co/kUVHoonTNq
0
0
0
Acquired resistance to Cancer Immunotherapy Free at https://t.co/glUzN48hpS ➡️ Metastatic cancers can be cured ➡️ Pts who initially respond can develop resistance (up to 65% of responders) ❗One of the top priorities in Oncology Reviewed in @TrendsMolecMed
@CCITdk @MdCurioni
2
1
4
New #JITC article: Arginase-1-specific T cells target and modulate tumor-associated macrophages https://t.co/iESJP1o0oh
@marper2323 @CCITdk
0
3
11
🎉Cell Therapy Milestone 👍This week, a patient with melanoma received the first non-viral CRISPR-edited TIL infusion product at @CCITdk Congrats to Cell Therapy team @ozcan_met: from preclinical https://t.co/PEDqa1pDlP to GMP grade https://t.co/WWmXHr8Z1w
0
2
3
📢 Check out this special case report by Monberg, Svane & colleagues @CCITdk @helsinkiuni @Rigshospitalet 🇩🇰🇫🇮. 💉Combined treatment with TILs + oncolytic adenovirus (TILT-123) in a patient with metastatic mucosal melanoma. Available #OpenAccess 👇 https://t.co/11jzDB280O
esmoiotech.org
Despite significant advancements in the treatment of malignant melanoma, metastatic mucosal melanoma remains a therapeutic challenge due to its complex pathogenesis, distinct pathological character...
0
2
3
📣 PhD course "Cancer Immunology and Immunotherapy", 4th edition 📃 Course Description and registration 👉 https://t.co/sy4lHLrQgL ▶WHEN: 07-11/04/2025 (mon-fri) ▶WHERE: Copenhagen Area, Denmark 📩 Full program available soon! Previous edition at https://t.co/wAbMb0fEj6
0
1
3
📢The Copenhagen Symposium on T Cell Therapy and Cellular Engineering (CATC) 2024 ⏰ 24-25 September 2024 📍 Greater Copenhagen, Denmark More at https://t.co/QcwdKG0Z6V
catc.dtu.dk
0
0
2
New publication on #MPNsm from @CCITdk published in @BrJHaem: Peripheral blood lymphocytes (PBL) from patients with CALR mutant #MPNsm display increased levels of surface TGFb and GARP. Probably mediated by enhanced binding of activated platelets to PBL. https://t.co/qhz3r2lVFR
onlinelibrary.wiley.com
T cells (green) and NK cells (purple) from patients with CALR exon 9 mutant myeloproliferative neoplasms display increased expression of LAP and GARP on their cell membrane compared with patients...
0
3
13
📣 Webinar "Adoptive cell immunotherapies for cancer" SN Oncology Webinar Series on 14 May at 4 pm CEST by @SpringerNature 👉 Free registration at: https://t.co/Ft7ZjtuPeo 👩🔬 Speaker: Inge Marie Svane, Director of @CCITdk 👨🎓 Chair: Luca Danelli, Senior Editor @NatureComms
0
2
8
💬 Fantastic keynote lecture by Dr. Inge Marie Svane from @CCITdk on TIL therapies at VHIO under the framework of #PragamTIL Annual Meeting.
0
5
14
Despite manufacturing costs ~67 000 €, academic TIL therapy for patients with #melanoma is both cost-saving and cost-effective in 🇩🇰 and 🇱🇺 Publicly-funded #celltherapy can be sustainable!
New #JITC article: Cost-effectiveness of treating advanced melanoma with tumor-infiltrating lymphocytes based on an international randomized phase 3 clinical trial https://t.co/ezppPmHVuX
@DoniaMarco @tenHamR @HaanenJohn @ValescaRetel
0
5
28
Excited to share our latest article on @jitcancer, where we show that a TGFβ-based immune modulatory vaccine can both directly and indirectly modulate the phenotype of TAMs and CAFs, two high TGFβ-secreting cell subsets in the TME ➡ https://t.co/vSW0WTKau2
@CCITdk
1
4
12
New #JITC review: Biomarkers for response to TIL therapy: a comprehensive review https://t.co/LvHD0jOwHS
@Vic_albarran @pballestin @DoniaMarco
0
23
55
📣 The Neoantigen Based Cancer Vaccine Pipeline at Dana Farber Cancer Institute 👨⚕️ by Derin Keskin https://t.co/LJg2SQcpZr 🕰 March 8th 2024 at 9.15 📍 Auditorium H2, Herlev Hospital, DK 💻Online at https://t.co/wOe4f91EbB ‼️Join this seminar, No registration required‼️
0
0
2
🔬 Murine Models for Cancer Immunotherapy, an analysis of tumor microenvironment (TME) compositions 🐭 Insights into comparative roles of the Lymphoid, Myeloid, and Stromal cell compartments of these models from the TSMI group here in @CCITdk More at 👉
1
0
3
Harnessing neoantigen-specific T cells for precision cancer immunotherapy 👉 @NatRevClinOncol, Jan 2024, free access link at https://t.co/PNnpM5Uzfp 💬 about "Phenotypic signatures of circulating neoantigen-reactive CD8+ T cells in patients with metastatic cancers" @YosephRami
3
15
54
Published today! Dissecting tumor microenvironment heterogeneity in syngeneic mouse models: insights on cancer-associated fibroblast phenotypes shaped by infiltrating T cells https://t.co/IYSMMMyovS
@CCITdk @FrontImmunol
frontiersin.org
Murine syngeneic tumor models have been used extensively for cancer research for several decades and have been instrumental in driving the discovery and deve...
0
1
4
#Postdoc position in Cancer #Immunotherapy 👉 https://t.co/ews5vdpoGX You get all at once: 1️⃣ Exciting project in the most 🔥 topic (acquired resistance) 2️⃣ Access to ALL you need at fantastic @CCITdk 3️⃣ The most collaborative team on 🌍 https://t.co/bUbdMem17i with me as🧑✈️
0
7
17
PD-L1 status to select for ipilimumab+nivolumab in #melanoma 👉 https://t.co/2TGUG9CAw7 (Eur J Cancer) ✅ PD-L1≥1%: same outcome, regardless of combo or anti-PD-1 mono ✅ PD-L1<1%: improved PFS with combo Real-world, propensity score matched analysis of an entire-country cohort
0
24
54